Trial Profile
Phase I/II Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Ixazomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 24 Jul 2022 route and form added from study protocol doc.
- 30 Sep 2020 Status changed from active, no longer recruiting to completed.
- 08 Jul 2020 Planned End Date changed from 1 May 2020 to 1 May 2021.